Last reviewed · How we verify
Peginterferon alpha
At a glance
| Generic name | Peginterferon alpha |
|---|---|
| Also known as | PegIntron, SCH 054031, MK-4031 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B
- Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM (PHASE2)
- Peg-interferon for Inactive Chronic Hepatitis B Carriers (PHASE2, PHASE3)
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C (PHASE1, PHASE2)
- Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis (NA)
- Efficacy and Safety of Peginterferon in ET and PV. (NA)
- Pegasys® in Patients With Myeloproliferative Diseases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon alpha CI brief — competitive landscape report
- Peginterferon alpha updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI